





Clinical Evidence for CytoSorb® Therapy in Liver


Name	Title	Aim	Number of patients	Type of study	Outcome
Riva et al., J Art Orgs 2023; epub	Extracorporeal Liver Support Techniques: a comparison	Compared 17 pts who had 28 CytoSorb® treatments with; 19 pts who had 37 coupled plasma filtration adsorption (CPFA) treatments; 1 pt who had 3 MARs treatments; 1 pt who had 5 prometheus treatments; and 1 pt who had 2 plasma adsorption perfusion treatments.	39	Retrospective comparative analysis	CytoSorb® showed a significantly higher adsorption ability for Total Bilirubin (TB) and direct bilirubin (DB) compared to CPFA. Comparing all techniques, CytoSorb® was the most efficient system.
Popescu et al., J Clin Med 2023; 12(6):2258	Artificial Liver Support with CytoSorb® and MARS in Liver Failure: A Retrospective Propensity Matched Analysis	Comparison CytoSorb® & Molecular Adsorbent Recirculating System (MARS) in liver failure patients	15 v 15	Retrospective cohort study	CytoSorb® associated with decreased bilirubin, ammonia, lactate and transaminases compared to MARS gp with a 10 point decrease in the Model for End-State Liver Disease (MELD) score
Ocskay et al., J Clin Med 2021; 10(21):5182	Hemoadsorption in 'Liver Indication' - Analysis of 109 patients' data from the CytoSorb® international registry.	Analysis of 'liver indication' subgroup patients from the CytoSorb® International Registry (total 1434 patients).	109	Registry	Baseline serum bilirubin levels were significantly reduced pre versus post CytoSorb® use.
Scharf et al., Sci Rep 2021; 11(1); 10190	Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study.	Compare bilirubin removal by CytoSorb® with removal by ADVOS in patients with acute liver failure (various etiologies).	33	Case series	Both devices led to significant bilirubin removal & lower than expected mortality rates but only CytoSorb® use resulted in hemodynamic stabilization and was much easier to use.





Clinical Evidence for CytoSorb® Therapy in Liver

Name	Title	Aim	Number of patients	Type of study	Outcome
 Tomescu et al., Int J Artif Organs 2021; 44(8): 560-4	Haemoadsorption by CytoSorb® in patients with acute liver failure: a case series.	Assess clinical effects of CytoSorb® in biochemical parameters in patients with acute liver failure. Patients treated with 3 consecutive 24 hrs sessions.	28	Case series	Suggest use of CytoSorb® as a therapeutic option for management of liver impairment providing biochemical control, aiding bridge to liver transplantation, or until spontaneous remission.



CytoSorbents Europe GmbH

Müggelseedamm 131
12587 Berlin | Germany

T +49 30 65 49 91 45
F +49 30 65 49 91 46
support@cytosorbents.com

Register for the literature newsletter

Visit our literature database for an overview of all references



www.cytosorb.com

The clinical and preclinical data and results obtained with the CytoSorb® adsorber are not transferable to other products. CytoSorb® should only be administered by health care professionals, properly trained in administration of extracorporeal therapies. The statements here represent the personal opinions and views of the author(s) only and do not necessarily reflect accepted medical knowledge in general or indications covered by the intended use of CytoSorb®. CytoSorb® and CytoSorbents are trademarks of the CytoSorbents Corporation, USA. © Copyright 2023, CytoSorbents Europe GmbH. All rights reserved. B1297R02ENG2023